Blue Belt Technologies has received clearance from the U.S. Food and Drug Administration to market its latest surgical application for the Navio Surgical System — patellofemoral joint replacement surgery.
The new application expands the Navio Surgical System's indications from unicondylar knee replacement to offer the full suite of partial knee replacement options.
"We focus our technology development efforts on clinically relevant applications that can benefit from reproducible precision. Adding patellofemoral replacement was the logical next step for us. This PFJ application will continue to arm our surgeon customers with the next-generation in robotics-assisted tools to safely and effectively treat a greater population of patients," said Eric Timko, president and CEO of Blue Belt Technologies in a news release.
More Articles on Devices:
5 Key Results: LDR's Mobi-C Artificial Disc Replacement vs. ACDF
FDA Clears AccelSPINE's Next Generation Minimally Invasive Spine System
Global Medical Device Market to Grow at 6.2% Annually Until 2018